This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading statements to the public about their Covid-19 vaccines. And the move comes after Moderna was chastised for the second time in five months by a U.K. trade group over its attempts to recruit children into a late-stage clinical trial for its Covid shot.
A report by Cervicorn Consulting forecasts that the pharmaceutical water market will value $96.25 billion by 2033, with a CAGR of 9.26 percent between 2024 and 2033. Key drivers include a rise in demand for high-quality water in the pharmaceutical industry, automation and government initiatives. The research suggests that during the forecast period, the market will emphasise addressing the challenges associated with limitations with manual monitoring processes and operational efficiencies.
Corbus Pharmaceuticals on Friday presented new data from the first Western study of its antibody-drug conjugate treatment for cancer that largely mirrored previous results reported from China. In a study conducted in the U.S. and the U.K., the Corbus drug, called CRB-701, showed an overall response rate of 27% from 26 evaluable patients with nine different types of cancer — all in advanced stages.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe’s reaction to talk of an academic brain drain in the U.S., and more.
Editor's Note: This is a developing story. If you are a dismissed or active federal worker with information to share, please reach out at ntong@questex.com. | The federal government is laying off thousands of health agency workers and others this week. Here's what we know so far.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Editor's Note: This is a developing story. If you are a dismissed or active federal worker with information to share, please reach out at ntong@questex.com. | The federal government is laying off thousands of health agency workers and others this week. Here's what we know so far.
Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.
In a party-line vote late Thursday, the House Budget Committee passed a budget blueprint that tees up the debate over tax cuts and how to pay for them, which is expected to include cuts to Medicaid. The House budget resolution bill sets the levels for minimum spending cuts and a maximum deficit increase for each committee under the budget reconciliation process.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The dismissals will free up over $98 million annually which will be redirected to veterans' care, benefits and services, the department said. The cuts are part of the White House's broader directive to slash federal workforces.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Hi there! I’m Sarah — former Morning Rounds editor, current STAT reporter, and your friendly sub today.
After gradually consuming increased doses of peanut butter, children who could initially tolerate about half a peanut could consume 3 tablespoons without an allergic reaction.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
VoiceCare AI also started piloting its technology at Mayo Clinic to tackle patient pre-authorization and benefit confirmations within its neurology and pediatrics departments and medical and administrative support operations.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Discover how life science real estate clusters drive innovation and collaboration, leading to groundbreaking advancements in the industry. Explore the impact of these clusters and how they propel progress in life sciences.
Pharmacists can help patients and their caregivers manage seizures, assess seizure control, and recommend appropriate treatments such as phenobarbital or rescue medications.
Slynd is a progestin-only, estrogen-free hormonal contraceptive that prevents pregnancy primarily by suppressing ovulation. Slynd contains 24 active hormone pills and four placebo pills, for a total of 28 tablets. According to James Lyons, MD, Physician at Synergy Houses, some people notice lighter or less frequent bleeding on Slynd, but the placebo phase helps create a pattern that can feel more predictable and manageable.
The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the UK, and Japan - is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by 2033, according to leading data and analytics company GlobalData.
Therapies like the newly approved suzetrigine, a nonopioid NaV1.8 pain signal inhibitor, could revolutionize pain management and mitigate the risks associated with opioid use.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content